Conference Reports for NATAP

AASLD The Liver Meeting Boston MA November 2016 Back

HCV at AASLD / New HCV Drugs / New NASH Drugs       Hep C Articles...   AASLD: New HCV Drugs at AASLD - (11/21/16)   AASLD: Towards a Single Treatment Cure for HCV: Reformulation of the Pangenotypic NS5B NNI GSK2878175 as a Long Acting Parenteral (LAP) - (11/21/16)   AASLD: A Single Subcutaneous Dose of 2 mg/kg or 4 mg/kg of RG-101, a Galnac-Conjugated Oligonucleotide with Antagonist Activity against miR-122, Results in Significant Viral Load Reductions in Chronic Hepatitis C Patients - (11/29/16)   AASLD: Regulus Expands Clinical Trial Collaboration with GSK ....."potential single-visit cure" - (11/29/16)   AASLD: Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world - (11/21/16)   AASLD The Liver Meeting Boston MA November 2016